Background: This study was conducted to investigate the fertilization and embryo development of human oocytes injected at different time intervals after extrusion of the first polar body (PB) following in vitro maturation (IVM) in IVM cycles. Also, we evaluated whether spindle imaging could serve as a tool to determine the optimal ICSI time.
Methods: Oocytes were collected from 43 women with polycystic ovary syndrome. Metaphase I (MI) oocytes after in vitro culture for 24 h from germinal vesicle stage were subjected to ICSI according to time after first PB extrusion. The intervals were: within 1 h (n=38); 1-2 h (n=30); 2-4 h (n=26);4-6 (n=28) and 6-8 h (n=40). In some MI oocytes, viable spindle location was evaluated using Polscope microscopy at different time intervals after first PB extrusion.
Results: Fertilization rate of the MI oocytes injected within 1 h after first PB extrusion was low (15.8; 6/38) (P<0.01 versus all other times). In contrast, the fertilization rate was 80, 92.3, 82.1 and 85% for oocytes injected 1-2, 2-4, 4-6 and 6-8 h after first PB extrusion, respectively. Development of good-quality embryos was not significantly different among all the groups. Interestingly, all the oocytes injected within 1 h after first PB extrusion were in Telophase I.
Conclusions: Human oocytes matured in vitro needed at least 1 h after first PB extrusion to complete nuclear maturation. Use of a live spindle imaging system can help to decide the timing of ICSI for oocytes matured in vitro.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/humrep/dem124 | DOI Listing |
J Assist Reprod Genet
December 2024
Reproductive Medical Center, People's Liberation Army Joint Logistic Support Force 924Th Hospital, Guilin, Guangxi, People's Republic of China.
Purpose: Selection of optimal embryo transfer strategies for IVF patients treated with antagonist protocols.
Methods: A retrospective study was conducted to assess whether whole embryo culture to the blastocyst stage could enhance the cumulative live birth rate (CLBR). The study included data from the first oocyte retrieval cycle of 4131 patients who underwent IVF treatment between January 2018 and June 2022.
Hum Reprod
December 2024
Unit for Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Study Question: Is the probability of pregnancy different between women using biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART?
Summary Answer: Meta-analysis of eight randomized clinical trials (RCTs) suggests that live birth, clinical, and ongoing pregnancy rates are significantly lower with biosimilars of follitropin alfa compared to the originator.
What Is Known Already: All biosimilars of follitropin alfa have received regulatory approval by demonstrating non-inferiority in the number of retrieved oocytes compared to the originator. Nevertheless, the most clinically relevant outcome in ART for both clinicians and patients is live birth.
J Assist Reprod Genet
December 2024
The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, 1305 York Avenue, Y720, New York, NY, 10021, USA.
Hum Reprod Update
December 2024
Division Woman and Baby, Reproductive Medicine, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.
Background: The ovarian response to gonadotropin stimulation varies widely among women, and could impact the probability of live birth as well as treatment risks. Many studies have evaluated the impact of different gonadotropin starting doses, mainly based on predictive variables like ovarian reserve tests (ORT) including anti-Müllerian hormone (AMH), antral follicle count (AFC), and basal follicle-stimulating hormone (bFSH). A Cochrane systematic review revealed that individualizing the gonadotropin starting dose does not affect efficacy in terms of ongoing pregnancy/live birth rates, but may reduce treatment risks such as the development of ovarian hyperstimulation syndrome (OHSS).
View Article and Find Full Text PDFSleep Med
November 2024
Department of Reproductive Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China; Hubei Clinical Research Center for Prenatal Diagnosis and Birth Health, Wuhan, China; Wuhan Clinical Research Center for Reproductive Science and Birth Health, Wuhan, China. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!